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A 336-amino-acid segment of the GB virus C second envelope protein (E2) has been produced in BHK-21 cells using the
Semliki Forest virus vector system. Secretion of this protein was facilitated by deletion of a hydrophobic region at the C-
terminus that may represent the membrane anchoring domain. The E2 protein recovered from the culture supernatant
exhibited a molecular mass of approximately 52 kDa, with the increase in size relative to the polyprotein backbone being
contributed by N-linked glycosylation. A radioimmunoprecipitation assay using GBV-C E2 was developed to test for the
presence of antibodies against this protein in human sera. The prevalence of antibodies to E2 was high among injection
drug users and other individuals at risk for acquiring parenterally transmitted agents. There was a much higher percentage
of anti-E2 seropositivity in GBV-C RT-PCR negative compared to GBV-C RT-PCR positive samples from these populations.
In addition, serial samples from patients transfused with blood containing GBV-C showed seroconversion to anti-E2 positivity
and loss of GBV-C viremia as measured by RT-PCR within 11 months of transfusion in five of seven individuals. Thus, this
system provided a rapid means to identify GBV-C E2 as a useful antigen for the study of GBV-C exposure. q 1996 Academic
Press, Inc.
INTRODUCTION been hampered since only about 25% of GBV-C infected
individuals develop antibodies to Escherichia coli-ex-
GB virus C (GBV-C) is a newly described human virus pressed GBV-C proteins in their sera as detected by
which possesses a single-stranded RNA genome ap- Western blot or solid-phase enzyme-linked immunosor-
proximately 10 kb in size. GBV-C has been tentatively bent assay (ELISA) (Dawson et al., 1996; Pilot-Matias et
classified as belonging to a virus group within the Flavi- al., 1996). Most of the seropositive individuals produce
viridae containing hepatitis C virus (HCV) and two other antibodies against only a single antigen. In addition, no
viruses isolated recently, designated GB virus A (GBV-A) single GBV-C antigen has been identified thus far that is
and GB virus B (GBV-B) (Leary et al., 1996; Muerhoff et consistently recognized by individuals who have been
al., 1995; Simons et al., 1995a,b). The newly described exposed to GBV-C. However, the current immunoassays
hepatitis G virus (Linnen et al., 1996) appears to be an are limited by the use of GBV-C proteins that have been
isolate of GBV-C (Zuckerman, 1996). Studies indicate that denatured during purification. In addition, the structural
GBV-C is found in the sera of commercial plasma donors, proteins currently in use are not glycosylated.
people at risk for parenterally transmitted infectious The phylogenetic relatedness of GBV-C and HCV sug-
agents such as injection drug users, and some individu- gested that useful serologic markers for GBV-C infection
als with hepatitis of unknown origin (Dawson et al., 1996; may be identified in regions homologous to those identi-
Leary et al., 1996; Simons et al., 1995a; Yoshiba, Oka- fied as useful for HCV. One of the most important markers
moto, and Mishiro, 1995). for HCV is the nucleocapsid or core protein (Chiba et al.,
Although some regions of GBV-C have been identified 1991; Nasoff et al., 1991; and others). However, GBV-C
as immunogenic (Pilot-Matias et al., 1996), efforts to de- does not appear to encode a core-like protein (Erker et
velop an immunoassay for the detection of GBV-C have al., 1996; Leary et al., 1996; Muerhoff et al., 1996; Simons
et al., 1996). Glycosylated E2 protein is another useful
marker in HCV infection (Lesniewski et al., 1995; Lok et1 A preliminary report of this work was presented in a poster at
the IX Triennial International Symposium on Viral Hepatitis and Liver al., 1993; Zaaijer et al., 1994). Therefore, we evaluated
Disease held April 21–25, 1996 in Rome, Italy. whether the GBV-C E2 protein expressed in mammalian
2 To whom reprint requests should be addressed at Abbott Labora- cells would provide a useful antigen for GBV-C preva-tories, Department 90D, Building L3, 1401 Sheridan Road, North Chi-
lence studies. In the present study, a C-terminally trun-cago, IL 60064-4000. Fax: (847) 938-6042. E-mail: pilottj.add@notes.
abbott.com. cated GBV-C E2 protein (E2-336) was expressed in baby
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hamster kidney (BHK-21) cells using the Semliki Forest
virus (SFV) vector system (Liljestrom and Garoff, 1991).
The protein was secreted and glycosylated. A sensitive
and specific radioimmunoprecipitation assay (RIPA) was
developed and shown to be useful in identifying individu-
als who have been exposed to GBV-C.
MATERIALS AND METHODS
Rabbit and human antisera
Rabbit antisera were generated as follows: 15-week-
old female New Zealand white rabbits weighing 2–3 kg
were inoculated both intramuscularly and subcutane-
ously for all injections, with 1 mg primary inocula fol-
lowed by 0.2- to 0.5-mg boosts at 1, 2, and 4 months.
Three different hyperimmune rabbit sera reactive with
GBV-C E2 were used. The first rabbit (10363) was immu-
FIG. 1. Construction of pSFV-ss plasmid. Two synthetic oligonucleo-
nized with protein derived from clone C29. This clone tides were annealed and ligated into the BamHI site of pSFV1. The
encodes a 212-amino-acid portion of GBV-C E2 (amino oligonucleotide duplex encoded a human lysozyme secretion signal
acids 209–420 of GBV-C; GenBank Accession No. as shown. The upstream overhang was compatible with a BamHI site,
but after ligation the regenerated sequence was GGATCA. This allowed1572850) expressed in E. coli as a CKS fusion protein as
insertion of a fragment encoding GBV-C E2 into the unique BamHIpreviously described (Dawson et al., 1996). The second
site downstream of the lysozyme signal sequence. The plasmid was
rabbit (10365) was immunized with a 30-mer synthetic linearized at the unique SpeI restriction site prior to RNA transcription
peptide derived from the E2 region of GBV-C, encom- using the SP6 promoter.
passing amino acids 335 –364. The third rabbit (10692)
was immunized with a purified 315-amino-acid portion
performed with the Ausria II assay and the antibodiesof GBV-C E2 (amino acids 204–518; E2-315) expressed
against HBV core antigen were determined with the Cor-in and secreted from Chinese hamster ovary (CHO) cells.
zyme test. All tests are commercially available from Ab-Two hyperimmune rabbit sera reactive with HCV E2 were
bott Laboratories, North Chicago, Illinois. The details ofused. The first (6512) was generated by immunization
the GBV-C E2 and HCV E2 ELISAs have been presentedwith a 43-mer synthetic peptide encompassing amino
elsewhere (Dille et al., 1996; Lesniewski et al., 1995).acids 509–551 of HCV-1 and the second (9482) was gen-
Conditions for reverse-transcription–polymerase chainerated by immunization with purified HCV E2 protein ex-
reaction (RT-PCR) on human serum samples were pre-pressed in and secreted from CHO cells (Lesniewski et
viously described (Dawson et al., 1996).al., 1995). The endpoint titer for each rabbit serum ranged
from 1 1 107/ml to 5 1 107/ml against the homologous
SFV expression plasmid constructionimmunogen.
Human sera from individuals considered at low risk for The human lysozyme secretion signal was inserted
exposure to GBV-C were obtained from volunteer blood into the pSFV1 expression plasmid (Gibco-BRL; Grand
donors residing in the United States. These specimens Island, NY) by cloning of an oligonucleotide duplex into
had normal serum alanine aminotransferase (ALT) levels BamHI-digested pSFV1 as shown in Fig. 1. When the
(£50 IU/ml) and were unreactive for hepatitis B (HBV) resulting plasmid, pSFV-ss, was digested with BamHI,
surface antigen, antibodies to HBV core, and antibodies the upstream site was not cut due to a mutation in the
to HCV. Human sera from several populations consid- BamHI recognition site. This allowed cloning of the GBV-
ered at risk of acquiring parenterally transmitted viruses C E2 gene at the downstream BamHI site such that the
were previously described (Dawson et al., 1996). These first amino acid encoded by the E2 gene followed the
included specimens from injection drug users, commer- signal peptidase cleavage site encoded by the lysozyme
cial plasma donors, individuals who had received multi- signal sequence-plus 2 linker amino acids encoded by
ple transfusions, and individuals with cryptogenic non- the restriction site.
A-E hepatitis. Sera from individuals transfused with GBV- A fragment encoding amino acid residues 204–539 of
C were from the Transfusion-Transmitted Viruses Study the GBV-C polyprotein (GBV-C E2-336) was generated by
(Aach et al., 1991). PCR from a plasmid template using primers 5*-AAA-
ATTGGATCCAGGCGCGCCCGCCTCAGTGTTG and 5*-
Enzyme immunoassays and RT-PCR AAAACCGGATCCTTACGGAATGAAGTTGCCCGCATCC
at 1 mM for 25 cycles (947 for 20 sec; 557 for 30 sec; 727Testing for HCV was performed with an HCV EIA sec-
ond generation assay. HBV surface antigen testing was for 60 sec). The resulting PCR fragment was digested
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with BamHI (sites are underlined in primer sequences) flask, and incubated at 377 and 5% CO2 . Transfection
efficiencies were routinely observed to be 95–100% us-and ligated into BamHI-digested pSFV-ss, resulting in
plasmid pSFV-ss/E2-336. The sequence was confirmed ing RNA derived from the Lac-Z positive control plasmid
pSFV3-lacZ and b-galactosidase assay reagents as sup-using an ABI Prism Dye Terminator Cycle Sequencing
Ready Reaction Kit and an ABI 373 automated sequencer plied and described by Gibco-BRL.
(Perkin–Elmer, Corp.; Foster City, CA).
Metabolic labeling of transfected BHK-21 cellsA fragment encoding amino acid residues 388–664 of
the HCV-1 polyprotein (HCV E2-277) was generated by
After incubation at 377 and 5% CO2 for 5 hr, the growthPCR from a plasmid template using primers 5*-AAA-
medium was removed and the cells were washed three
ATTGGATCCCACCGGGGGAAGTGCCGGCCAC and 5*-
times with D-PBS with calcium and magnesium (Gibco-
AAAACCGGATCCTTACGGGCTGAGCTCGGACCTGTC
BRL). Cells were overlaid with minimum essential me-
using the same conditions as above. The PCR fragment
dium (MEM) without cysteine (MEM Select-Amine kit,
was cloned (resulting in plasmid pSFV-ss/HCV-E2-277)
Gibco-BRL). A culture vessel surface area to medium
and sequenced as above.
volume ratio of 25 cm2 to 2 ml was maintained. [35S]-
Cysteine (Amersham Life Sciences; Arlington Heights,Generation of RNA transcripts
IL) was added to a final concentration of 75 mCi/ml and
cells were incubated at 377 and 5% CO2 for 48 hr, atPrior to in vitro synthesis of RNA, pSFV-ss/E2-336 and
pSFV-ss/HCV-E2-277 were linearized at the SpeI restric- which time the cells and supernatants were harvested.
Supernatants were collected and spun at 1000 g to pellettion site downstream of each of the inserted fragments.
After digestion, the DNA was extracted with phenol:chlo- any nonadherent cells prior to analysis. Adherent cells
were washed three times in D-PBS with calcium androform:isoamyl alcohol (25:24:1), precipitated with etha-
nol, and resuspended in DEPC-treated H2O. RNA was magnesium and overlaid with lysis buffer (1% Nonidet-
P40, 50 mM Tris–HCl, pH 7.6, 150 mM NaCl, 2 mM EDTA,synthesized using the InvitroScript CAP SP6 In Vitro Tran-
scription Kit (Invitrogen Corp.; San Diego, CA) as directed 20 mg/ml PMSF). A surface area to volume ratio of 25
cm2 to 250 ml of lysis buffer was maintained. Cells wereby the manufacturer. The synthesized RNA was divided
into approximately 5-mg aliquots (based on quantitation harvested from the culture vessel, combined with nonad-
herent cells and lysed on ice for 10 min.using agarose gel electrophoresis) and stored at 0707.
BHK-21 transfection and cell culture Analysis of protein expression in BHK-21 cells
Aliquots of labeled cell lysates or supernatants wereThe cell line BHK-21 (A.T.C.C. CCL-10) was obtained
from the American Type Culture Collection, Rockville, analyzed by SDS–polyacrylamide gel electrophoresis
(SDS–PAGE) under reducing conditions using standardMaryland. Cells were cultured in growth medium (Glas-
gow minimum essential medium with 2 mM glutamine, methods and reagents. After electrophoresis, gels were
fixed in 10% acetic acid/40% methanol, dried, and ana-10% tryptose phosphate broth, 5% fetal calf serum, 30 mM
HEPES, 100 U/ml penicillin/streptomycin) (Gibco-BRL) at lyzed using a Molecular Dynamics PhosphorImager
(Sunnyvale, CA). Quantitation of individual bands was377 and 5% CO2 . Cells were harvested by removing the
growth medium and rinsing three times with Dulbecco’s done using ImageQuaNT, Version 4.2 software (Molecu-
lar Dynamics). RIPAs were performed on labeled cellphosphate-buffered saline without calcium and magne-
sium (D-PBS) (Gibco-BRL). Cells were then treated with supernatants as follows: Supernatants were preincu-
bated for 1 hr at 47 with Pansorbin cells (Calbiochemtrypsin EDTA (Gibco-BRL) for 5 min and the trypsin and
cell suspension were decanted. The cell suspension was Corp.; La Jolla, CA). After centrifuging for 10 min at 10,000
g, an aliquot of the preadsorbed supernatant was mixedneutralized with growth medium and centrifuged at 1000
g to pellet the cells. with 2–8 ml of rabbit or human serum and incubated
at 47 for 2–4 hr. Protein A–agarose beads (BoehringerFor transfection, cells were grown to mid-log phase in
860-cm2 roller bottles and harvested from the culture Mannheim; Indianapolis, IN) were added and tubes were
incubated at 47 for 1 hr with rocking. The protein A –vessel as described above. After three D-PBS washes,
cell density was adjusted to 1 1 107 cells in 0.8 ml of D- agarose beads were pelleted and washed twice with
lysis buffer (0.2% NP-40, 50 mM Tris, pH 8.0, 150 mMPBS. Cells were kept at room temperature for not more
than 30 min before electroporation. Approximately 5–10 NaCl), once with lysis buffer containing 0.2% SDS, once
with lysis buffer containing 500 mM NaCl and finally oncemg of RNA was mixed with the 0.8 ml of cell suspension
and immediately electroporated at 1250 V, 25 mF with with H2O. The beads were resuspended in sample buffer
(62.5 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 5% b-mer-three manual pulses using a Gene Pulser (Bio-Rad; Her-
cules, CA) and a 4-cm Gene Pulser cuvette. After 5 min captoethanol, and 0.1 mg/ml bromophenol blue) and
heated at 957 for 5 min. Supernatants were run on SDS–at room temperature in the electroporation cuvette, cells
were transferred to growth medium, planted in a T-75 PAGE, fixed, dried, and analyzed as described above.
AID VY 8227 / 6a21$$$662 10-17-96 13:36:56 vira AP: Virology
285EXPRESSION OF GBV-C E2 PROTEIN
For the deglycosylation experiment, the antibody –
GBV-C E2-336 protein complex was removed from the
protein A–agarose beads by heating at 957 for 5 min in
0.5% SDS, 50 mM b-mercaptoethanol, 50 mM Tris, pH
8.0. Two volumes of 2% NP-40 in 50 mM Tris, pH 8.0,
was added, followed by the addition of 0.5 units of recom-
binant N-glycanase (Genzyme; Cambridge, MA) and incu-
bation at 377 for 18 hr. Sample buffer was added, followed
by SDS–PAGE and PhosphorImaging as above. A control
reaction without the enzyme was performed under the
same conditions.
Purification of proteins expressed in CHO cells
Expression of a C-terminally truncated HCV E2 protein
(HCV E2-277) in CHO cells using the SV-HCL vector and
purification using successive cation, anion, and lectin
affinity chromatographies was previously described (Les-
niewski et al., 1995). Expression of GBV-C E2-315 in CHO
cells using the SV-HCL vector and purification by immu-
noaffinity chromatography using a monoclonal antibody
directed against a FLAG peptide encoded at the C-termi-
nus of the protein is described in detail elsewhere (Sur-
owy et al., manuscript in preparation). The N-terminus of
the purified CHO cell-derived GBV-C E2-315 has been
sequenced and found to be correct (Surowy et al., manu-
script in preparation).
RESULTS
Expression of GBV-C E2 protein and analysis of N-
linked glycosylation
A 336-amino-acid segment of the GBV-C E2 antigen
was expressed in BHK-21 cells using the Semliki Forest
virus expression system and the human lysozyme secre-
tion signal sequence. The E2 protein was truncated just FIG. 2. Immunoprecipitation and N-glycanase treatment of GBV-C
upstream of a hydrophobic domain found at the C-termi- E2 protein. (A) Lysate (L) and supernatant (S) fractions from pSFV-ss/
E2-336 were harvested after 48 hr of metabolic labeling and analyzednus. The predominant protein found in the cell lysate
by 10% SDS–PAGE. pSFV-ss/E2-336 lysate and supernatant were im-from pSFV-ss/E2-336 was a broad band with a molecular
munoprecipitated using preimmune and hyperimmune anti-GBV-C E2mass of approximately 35 –46 kDa, while that in the cul-
rabbit sera 10363 and analyzed as above. Two additional supernatant
ture supernatant fraction was a somewhat less broad samples were immunoprecipitated with the hyperimmune 10363 rabbit
band with a molecular mass of approximately 48–56 kDa sera as above and then incubated overnight at 377 in the absence (0)
or presence (/) of N-glycanase. (B and C) Rabbit and human sera(Fig. 2A, lanes 1 and 2). The 35- to 46- and 48- to 56-
were used to immunoprecipitate pSFV-ss/E2-336 supernatant (B) orkDa proteins were specifically precipitated from the ly-
pSFV-ss/HCV-E2-277 supernatant (C) and analyzed by 10% SDS–PAGE.sate and supernatant, respectively, with hyperimmune
Lanes 1, 3, 5, 7, and 9 are RIPAs with preimmune rabbit sera and lanes
anti-GBV-C E2 rabbit serum 10363, but not with the pre- 2, 4, 6, 8, and 10 are RIPAs with hyperimmune rabbit sera as indicated.
immune serum from the same rabbit (Fig. 2A, lanes 4 and Lanes 11 and 12 are RIPAs with sera from two injection drug users
and lanes 13 and 14 are RIPAs with sera from two volunteer blood6 versus lanes 3 and 5) confirming that the radiolabeled
donors. The positions of the molecular weight markers are indicatedproteins were GBV-C E2. Based on quantitiation of the
on the left.35- to 46- and 48- to 56- kDa bands in the lysate and
supernatant, respectively, approximately 30–35% of the
E2 made during the 48-hr labeling period was secreted lysate and supernatant were glycosylated. However, the
protein remaining inside the cell (lysate) exhibited afrom the cells into the medium.
The diffuse nature of the bands and the increased size lower molecular mass than the secreted form, indicating
that further processing had occurred during secretion.relative to that predicted for unmodified protein (36 kDa)
suggested that the GBV-C E2-336 proteins seen in the To confirm that the SFV-expressed GBV-C E2-336 was
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glycosylated, the protein found in the supernatant was
immunoprecipitated using anti-GBV-C E2 rabbit serum
10363 and then treated with N-glycanase (Fig. 2A, lane
8). A molecular mass shift from approximately 52 kDa
to approximately 35 kDa was noted after the treatment,
suggesting that the increase in size of the E2 protein
found in the supernatant was due to the presence of N-
linked oligosaccharides.
Specificity of GBV-C and HCV E2 RIPAs
In order to demonstrate the specificity of our assays,
RIPAs were performed with several additional sera. The
48- to 56-kDa protein in the supernatant was precipitated
with GBV-C E2 reactive sera from two other hyperimmune
rabbits (10365 and 10692) in addition to rabbit 10363
serum (Fig. 2B, lanes 8 and 10). Hyperimmune sera from
all three of these rabbits react with purified GBV-C E2-
FIG. 3. RIPAs on sera from injection drug users. (A) Sera from six315 and do not react with other proteins in spent cell
GBV-C RT-PCR negative injection drug users (1–6), six GBV-C RT-PCRculture medium from CHO cells secreting E2-315 (data
positive injection drug users (7–12), and one GBV-C RT-PCR negative
not shown). Preimmune sera from these rabbits did not volunteer blood donor (13) were used to immunoprecipitate pSFV-ss/
precipitate the 48- to 56-kDa protein from the supernatant E2-336 supernatant and analyzed by 10% SDS–PAGE as described
under Materials and Methods. The negative control (N) serum sample(Fig. 2B, lanes 7 and 9), nor did hyperimmune sera from
was from a volunteer blood donor previously shown to be negative fortwo rabbits (6512 and 9482) immunized with HCV E2
antibodies to GBV-C E2 by RIPA and ELISA. (B) Sera from GBV-C RT-protein or synthetic peptide (Fig. 2B, lanes 2 and 4). In
PCR negative injection drug users 1–3 and from volunteer blood donor
contrast, HCV E2-277 protein expressed and secreted in 13 were used to immunoprecipitate pSFV-ss/E2-336 supernatant as
the BHK-21/SFV system was not immunoreactive with above or in the presence of 0.4–4.0 mg unlabeled, purified HCV E2-
277 protein (/ HCV E2) or unlabeled, purified GBV-C E2-315 proteinany of the three GBV-C E2 hyperimmune rabbit sera (Fig.
(/ GB E2) to analyze the level of cross-reactivity of anti-GBV-C E22C, lanes 6, 8, and 10), but was immunoreactive with
antibodies with HCV E2 protein. The positions of the molecular weightboth of the hyperimmune rabbit sera specific for HCV E2
markers are indicated on the left.
(Fig. 2C, lanes 2 and 4).
Specificity was demonstrated by RIPAs with four hu-
man sera as well. The first of these was from an injection mg) of purified, unlabeled CHO cell-derived GBV-C E2-
drug user whose serum was immunoreactive with both 315 protein but not by an equivalent amount of purified,
CHO cell-derived GBV-C E2-315 by ELISA (Dille et al., unlabeled CHO cell-derived HCV E2-277 protein. Based
1996) and CHO cell-derived HCV E2-277 by ELISA (un- on quantitation of the individual bands using Im-
published data), while the second was from an injection ageQuaNT software, greater than 95% of the reactivity
drug user whose serum was immunoreactive with HCV with the GBV-C E2 protein was blocked in all four sam-
E2-277 (unpublished data) but not with GBV-C E2-315 by ples, again demonstrating the specificity of the anti-GBV-
ELISA (Dille et al., 1996). The third and fourth human C E2 reactivity in these samples.
serum specimens were from volunteer blood donors, one
of whom was shown to be anti-HCV E2-277 negative Anti-GBV-C E2 seroprevalence in injection drug users
(unpublished data) and anti-GBV-C E2-315 positive by
ELISA (Dille et al., 1996), while the other was negative Sera from 40 injection drug users were tested by RIPA
using the pSFV-ss/E2-336 supernatant. The seropreva-for both proteins by ELISA. RIPA results with these four
sera (Figs. 2B and 2C, lanes 11–14) in each case con- lence of antibodies to HCV (99%) and HBV (75%) (Dawson
et al., 1996) indicated that this population is at very highfirmed the results previously determined by ELISA, thus
verifying the specificity of the RIPA assays. risk of exposure to parenterally transmitted agents.
Twenty-nine of the 40 specimens (72.5%) were anti-GBV-In order to rule out the possibility that the GBV-C E2-
336 RIPA was detecting crossreactive HCV E2 antibod- C E2 positive (Table 1). Of these 29 immunoreactive sam-
ples, 27 were GBV-C RT-PCR negative. RIPA results fromies, a blocking experiment was performed on four serum
samples (three anti-HCV E2 positive injection drug users six of the 27 GBV-C RT-PCR negative specimens are
shown in Fig. 3A (lanes 1–6). The results from 6 of theand one anti-HCV E2 negative volunteer blood donor)
using purified, CHO cell-derived GBV-C or HCV E2 pro- 13 GBV-C RT-PCR positive specimens are also shown in
Fig. 3A (lanes 7–12), including 1 of the 2 individualstein (Fig. 3B). Immunoprecipitation of radiolabeled GBV-
C E2-336 protein was inhibited by an excess (0.4–4.0 who were both GBV-C RT-PCR positive and anti-E2-336
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TABLE 1 addition, a sample from G.B. taken more than 30 years
later was still weakly positive in the GBV-C E2-336 RIPA
(data not shown).Number of Number (%) E2
Category samples RIPA Positive A total of 60 specimens from the commercial plasma
donor population were tested for antibodies to GBV-C
Injection drug users E2. Twenty-one of these samples were not included in
GBV-C PCR positive 13 2 (15.4%)
Table 1 because the GBV-C RT-PCR status has not beenGBV-C PCR negative 27 27 (100%)
determined. In the E2 testing, the RIPA using the GBV-CNon-A-E hepatitis
GBV-C PCR positive 9 2 (22.2%) E2-336 protein expressed in BHK-21 cells and the ELISA
GBV-C PCR negative 5 2 (40%) using the GBV-C E2-315 protein expressed in CHO cells
Commercial plasma donors/multiply (Dille et al., 1996) were directly compared. Of the 60
transfused individuals
samples, 33 were positive in both assays while 27 wereGBV-C PCR positive 18 2 (11.1%)
negative in both assays. Thus, a 100% correlation in reac-GBV-C PCR negative 24 12 (50%)
Volunteer blood donors tivity was observed on this set of samples between the
GBV-C PCR positive 1 0 (0%) two systems, supporting the GBV-C E2 specificity of the
GBV-C PCR negative 59 2 (3.4%) assays.
Note. All volunteer blood donors were screened negative for HBsAg
Anti-GBV-C E2 seroprevalence in low risk patientsand for antibodies to HCV, HIV, and HBc.
Sera from 60 volunteer blood donors who were consid-
ered at low risk for parenterally transmitted agents andpositive (lane 8). In this specimen, the anti-E2-336 reactiv-
who tested negative for HBV, HCV, and HIV were alsoity was weak. An additional sample taken approximately
tested by the GBV-C E2-336 RIPA (Table 1). There was3 years later was available from each of the 2 individuals
one GBV-C RT-PCR positive sample in this population,who were both RT-PCR and RIPA positive. These new
and this specimen was found to be GBV-C E2-336 RIPAsamples were tested for both presence of viral RNA and
negative. In contrast, two GBV-C RT-PCR negative sam-for anti-E2 antibodies. The new sample from each individ-
ples from this population were immunoreactive with GBV-ual remained GBV-C RT-PCR positive and weakly anti-
C E2-336, one strongly reactive and one very weaklyE2-336 positive (data not shown). Nonetheless, a majority
reactive. The RIPA of the strongly reactive specimen is(11 of 13) of the GBV-C RT-PCR positive (i.e., viremic)
shown in Fig. 2B, lane 13 and in Fig. 3A, lane 13. A RIPAsamples from the injection drug users were GBV-C E2-
was also performed with this sample using the SFV-336 RIPA negative and all of the GBV-C RT-PCR negative
expressed HCV E2-277 protein. As shown in Fig. 2C, lanesamples from the injection drug users were GBV-C E2-
13, this sample was not reactive with HCV E2-277. Thus,336 RIPA positive.
the prevalence of exposure to GBV-C in this volunteer
donor population as detected by RT-PCR plus E2-336Anti-GBV-C E2 seroprevalence in additional high risk
RIPA was 5%.patients
RIPAs with the GBV-C E2-336 protein were performed Anti-GBV-C E2 seroprevalence in patients transfused
on sera from an additional 56 patients including commer- with GBV-C
cial plasma donors and individuals who had received
multiple blood transfusions, as well as on some individu- RIPAs were performed with the pSFV-ss/E2-336 super-
natant using serial blood samples from seven patientsals with cryptogenic non-A-E hepatitis (Dawson et al.,
1996) (Table 1). Of the 27 GBV-C PCR positive samples who were all RT-PCR negative for GBV-C prior to transfu-
sion. Subsequent to transfusion with blood containingin this group, 4 (14.8%) were anti-GBV-C E2-336 positive
by RIPA. Nine of the 27 PCR positive samples were from GBV-C, each of these seven individuals became GBV-C
RT-PCR positive within 3 months; four of the seven wereindividuals with non-A-E hepatitis and 2 of these 9 (22.2%)
were GBV-C E2-336 RIPA positive. The remaining 29 PCR positive within 3 weeks. Several of these individuals
developed elevated liver enzymes during the time whensamples in this group were GBV-C PCR negative, and of
these 14 (48.3%) were GBV-C E2-336 RIPA positive. Five they were GBV-C RT-PCR positive (Mosley et al., manu-
script in preparation). GBV-C E2-336 RIPA data on theof the 29 PCR negative samples were from individuals
with non-A-E hepatitis and 2 of these 5 (40%) were GBV- patients are shown in Table 2 and Fig. 4. Six of the seven
patients (patients 1–6) developed immunoreactivityC E2-336 RIPA positive. One interesting finding was that
an 8-week postpresentation sample from G.B., the sur- against the GBV-C E2-336 protein during the study pe-
riod, and five of these six individuals (patients 1–5) be-geon whose serum originally induced hepatitis in tama-
rins, leading to the isolation of GBV-A and GBV-B came GBV-C RT-PCR negative by their last available
sample. The time range within which these five individu-(Schlauder et al., 1995; Simons et al., 1995b), was
strongly positive by RIPA for GBV-C E2-336 protein. In als became GBV-C RT-PCR negative was from 6 to 11
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TABLE 2
Sample (days Sample (days
Patient posttransfusion) GBV-C PCR GBV-C E2 RIPA Patient posttransfusion) GBV-C PCR GB-C E2 RIPA
1 Donor / 0 5 Donor / 0
Recipient (01) 0 0 Recipient (01) 0 Weak /
Recipient (10) 0 0 Recipient (35) / Weak /
Recipient (18) / 0 Recipient (80) / /
Recipient (33) / 0 Recipient (106) / /
Recipient (46) / 0 Recipient (134) 0 /
Recipient (104) / 0 Recipient (169) 0 /
Recipient (117) / Weak / Recipient (184) 0 /
Recipient (154) / / Recipient (212) / /
Recipient (184) 0 / Recipient (239) 0 /
Recipient (207) 0 / Recipient (339) 0 /
Recipient (284) 0 / Recipient (428) 0 /
2 Donor 1 0 0 Recipient (522) 0 /
Donor 2 0 0 6 Donor 1 / 0
Donor 3 0 0 Donor 2 0 0
Donor 4 / 0 Donor 3 0 /
Recipient (0) 0 0 Donor 4 0 0
Recipient (8) / 0 Donor 5 / 0
Recipient (27) / 0 Donor 6 0 0
Recipient (48) / 0 Donor 7 0 0
Recipient (88) / Weak / Donor 8 0 —
Recipient (113) / / Donor 9 0 0
Recipient (185) / / Donor 10 0 0
Recipient (283) 0 / Recipient (0) 0 0
3 Donor 1 0 / Recipient (14) 0 Weak /
Donor 2 / 0 Recipient (41) 0 Weak /
Recipient (6) 0 0 Recipient (68) 0 0
Recipient (17) 0 0 Recipient (83) 0 0
Recipient (33) 0 0 Recipient (89) / 0
Recipient (45) 0 0 Recipient (105) / 0
Recipient (62) 0 0 Recipient (118) / 0
Recipient (75) / 0 Recipient (166) / 0
Recipient (90) / 0 Recipient (280) / /
Recipient (97) / 0 7 Donor 1 0 0
Recipient (151) / 0 Donor 2 0 0
Recipient (339) 0 / Donor 3 / 0
4 Donor 1 0 0 Donor 4 / 0
Donor 2 / 0 Recipient (01) 0 0
Donor 3 0 / Recipient (15) / 0
Recipient (02) 0 0 Recipient (43) / 0
Recipient (8) 0 0 Recipient (84) / 0
Recipient (15) / 0 Recipient (126) / 0
Recipient (43) / 0 Recipient (160) / 0
Recipient (64) / 0 Recipient (264) / 0
Recipient (85) / 0
Recipient (125) / 0
Recipient (145) / 0
Recipient (173) / 0
Recipient (278) 0 /
months after transfusion. Patient 5 was found to be patients 6 and 7 eventually became GBV-C RT-PCR nega-
tive or whether they remained positive for GBV-C RNA.weakly anti-E2-336 positive prior to transfusion, perhaps
indicating a past exposure to GBV-C. Patients 6 and 7 Patient 6 showed a weak, transient reactivity to E2-336
early after infection. One of this patient’s donors waswere still GBV-C RT-PCR positive on the last date of
sample availability. Patient 7 exhibited no immunoreac- strongly immunoreactive with E2-336, so the observed
reactivity may have resulted from carry-over of anti-E2tivity to the GBV-C E2-336 protein.
No further specimens were available from these pa- antibodies from this donor. In addition, due to lack of
sample availability, it was not possible to determine thetients. Therefore, it was not possible to ascertain whether
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lieved to closely resemble its native conformation and to
develop a sensitive RIPA to detect the presence in human
sera of antibodies directed at this protein. A soluble,
glycosylated form of the GBV-C E2 protein was secreted
into the cell culture medium. Secretion was facilitated
by truncating the protein just upstream of the putative
hydrophobic membrane anchoring domain at the C-ter-
minus. This strategy is analogous to that used to suc-
cessfully secrete HCV E2 protein (Lesniewski et al., 1995;
Spaete et al., 1992).
We have expressed in the SFV system the same 277-
amino-acid region of the HCV E2 protein previously pro-
duced in CHO cells (Lesniewski et al., 1995) and used it
to demonstrate the specificity of our RIPA assay using
hyperimmune rabbit sera as well as human sera. Addi-
tionally, a blocking experiment in which an excess of
unlabeled GBV-C or HCV E2 protein was added to the
GBV-C E2-336 RIPA demonstrated that the immunopre-
cipitation of GBV-C E2 protein by antibodies in the four
samples examined was not due to cross-reactivity withFIG. 4. RIPAs on sera from 2 patients transfused with blood con-
taining GBV-C. (A) Serial bleeds from an individual (patient number 2 anti-HCV E2 antibodies and was specific for the GBV-C
from Table 2) who received GBV-C RT-PCR positive blood from 1 of 4 E2 protein.
donors were used to immunoprecipitate pSFV-ss/E2-336 supernatant RIPAs using the GBV-C E2-336 protein were developed
and analyzed by 10% SDS–PAGE. Samples from the 4 donors and 8
to determine the presence of anti-GBV-C E2 antibodiesserial samples from the recipient were analyzed. The GBV-C RT-PCR
in various populations. However, due to the small sizestatus of the donors and that of each sample from the recipient are as
indicated. The negative (N) control was as described in the legend to of this study, results may not accurately reflect the preva-
Fig. 3. The positive (P) control was from a commercial plasma donor lence in these populations. The specimens chosen for
previously shown to be anti-GBV-C E2 positive by RIPA and ELISA. The
examination by RIPA were selected mainly because PCRpositions of the molecular weight markers are indicated on the left. (B)
data were available for each (Dawson et al., 1996). LargerSerial bleeds from an individual (patient number 4 from Table 2) who
received GBV-C RT-PCR positive blood from 1 of 3 donors were used prevalence studies using an ELISA that employs glyco-
to immunoprecipitate pSFV-ss/E2-336 supernatant as above. Samples sylated, purified GBV-C E2-315 secreted and purified
from the 3 donors and 10 serial samples from the recipient were ana- from CHO cells are ongoing. Thus far, a very high level
lyzed. The GBV-C RT-PCR status of the donors and each sample from
of correlation has been observed between the RIPA andthe recipient are as indicated. The positive (P) control was as described
the ELISA. Those samples which did not agree betweenabove. The positions of the molecular weight markers are indicated
on the left. the two assays were weakly positive in the RIPA assay
and fell just below the cutoff set for the ELISA, indicating
that the sensitivity of the RIPA is very similar to that
overlap between PCR positivity and anti-E2-336 reactivity obtained in the ELISA (unpublished data).
in patients 2, 3, and 4 in the time period between the
Results from our RIPA indicate that mammalian cell-
last two bleeds, which were several months apart.
expressed E2 protein is much more effective than E. coli-
expressed E2 protein at detecting individuals exposed
DISCUSSION to GBV-C (Dawson et al., 1996) and in fact is the only
seroconversion marker thus far identified. Several of theThe SFV expression system has advantages over
samples identified by the GBV-C E2-336 RIPA were alsomany other mammalian cell expression systems in
examined by Western blot analysis with CHO cell-ex-allowing rapid generation of constructs and in preferen-
pressed GBV-C E2-315 (Surowy et al., manuscript intially producing the protein of interest due to attenuation
preparation). Although concordance was seen on 7 sam-of host cell protein synthesis. This is at least partially
ples of the 20 GBV-C E2-336 RIPA positive samples ex-due to the fact that the SFV subgenomic RNA containing
amined, there were 13 E2 RIPA positive and ELISA posi-the cloned gene becomes the most abundant mRNA in
tive samples which were negative by Western blot, indi-the cell, recruiting a large portion of the cell’s transla-
cating the importance of conformational epitopes on thetional machinery. Additional mechanisms may also play
E2 protein for the detection of antibodies to E2. Similara role in the selective shut-down of host-specific protein
observations have been made for HCV and various flavi-synthesis (Sjoberg and Garoff, 1996). This analytical sys-
viruses, where at least some of the epitopes on the enve-tem has allowed us to rapidly express a 336-amino-acid
C-terminally truncated GBV-C E2 antigen in a form be- lope proteins are conformational in nature (Chien et al.,
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1993; Guirakhoo, Heinz, and Kunz, 1989; Hall et al., 1990; true causal link between the appearance of antibodies
to E2 and the loss of detectable GBV-C RNA in the serum,Lesniewski et al., 1995; Nowak and Wengler, 1987).
One hundred percent of the specimens examined from nor if individuals who become infected with GBV-C and
then mount an immune response to E2 and subsequentlythe injection drug user population were either GBV-C RT-
PCR positive or anti-GBV-C E2 antibody positive, indicat- clear the virus will have long-lasting protection from rein-
fection.ing a very high level of exposure to GBV-C, similar to the
high level of exposure to other parenterally transmitted There is a striking difference in the amount of se-
quence variation found among GBV-C E2 proteins rela-hepatitis agents seen in individuals from this population
(Dawson et al., 1996). Relatively high levels of exposure tive to that observed for HCV. E2 proteins from various
HCV isolates may have sequence identities as low asto GBV-C were also indicated by the seroprevalence of
antibodies to GBV-C E2 in commercial plasma donors 70%. In addition, a hypervariable region has been iden-
tifed near the N-terminus of HCV E2 which is believed(33.3%) and non-A-E hepatitis patients (28.6%). The major-
ity of E2 seropositive samples from these three popula- to allow the virus to ‘‘escape’’ neutralizing antibodies
(Farci et al., 1992; Weiner et al., 1992). No such hypervari-tions (41 of 47) were GBV-C RT-PCR negative. The obser-
vation that most of the individuals who possess antibod- able region has been found in the GBV-C E2 protein.
When the E2 proteins from four geographically diverseies to GBV-C E2 are GBV-C RT-PCR negative is in
contrast to the results for HCV, in which most of the isolates of GBV-C were aligned, sequence identities
were 90% (Erker et al., 1996). The level of sequenceindividuals identified as seropositive for antibodies to
HCV E2 are HCV RT-PCR positive (Lesniewski et al., variation observed between the E2 proteins from GBV-C
isolates more closely resembles that observed with the1995; Zaaijer et al., 1994).
The development of antibodies to E2 and subsequent envelope proteins of flaviviruses such as Dengue 2 virus
or pestiviruses such as bovine viral diarrhea virusloss of detectable viral RNA in five of the seven individu-
als transfused with GBV-C (Table 2) suggest that antibod- (Becher et al., 1994; Lewis et al., 1993). This lack of se-
quence variation in GBV-C E2 implies that this virus doesies to the GBV-C E2 protein may be involved in or at
least predictive of viral clearance. The PCR and RIPA not possess the ability to escape neutralizing antibodies
in the same manner as HCV and thus may explain thedata presented in Fig. 3 and Tables 1 and 2 are consis-
tent with the hypothesis that most individuals who elicit apparent clearance of GBV-C in most individuals follow-
ing detection of antibodies to the E2 protein.anti-E2 antibodies do not have virus present in the serum.
However, we cannot rule out the possibility that the virus Individuals who have been exposed to GBV-C seem
to segregate into two distinct populations. A majority ofis still replicating, but that the titer in the serum has
dropped below the limits of detection in our RT-PCR those exposed appear to resolve the viral infection. Most
of these individuals mount an antibody response to theassay. In addition, the observation that one of the trans-
fused patients (patient 5) was weakly immunoreactive E2 protein. Clearance of the virus may be due in part to
the immune response to the E2 protein as well as towith GBV-C E2 prior to transfusion suggests that in this
individual, the antibodies directed against E2 were not other mechanisms, such as T-cell mediated immunity. A
smaller but nonetheless significant percentage of individ-protective. This may have been due to the low antibody
titer or to prior infection with a different serotype of GBV- uals who contract GBV-C remain chronically infected and
most of these individuals do not appear to mount a hu-C, or it may indicate that other immune responses in
addition to antibodies directed at E2 are involved in the moral immune response to E2. However, 2 of the 40
injection drug users did not fit this profile. These individu-resolution of GBV-C infection.
It is tempting to speculate that GBV-C may be similar to als were both GBV-C RT-PCR positive and E2 seroposi-
tive on two separate dates 3 years apart. Whether thisflaviviruses such as dengue virus, Japanese encephalitis
virus, or yellow fever virus in which the envelope protein was due to reinfection with GBV-C during the study pe-
riod or whether these individuals were immunosup-plays a dominant role in the generation of neutralizing
antibodies and the induction of a protective immune re- pressed is not known.
Although the number of samples examined in thissponse (reviewed in Monath and Heinz, 1996). Similarly,
the E2 protein of pestiviruses has been shown to be study was limited, a high prevalence rate for GBV-C was
noted in the various high- and low-risk groups examined.the major target of neutralizing antibodies and induces
protective immunity (Donis et al., 1988; Rumenapf et al., The combined PCR plus E2 antibody prevalence rate of
5% in the volunteer blood donor group is particularly1991; Weiland et al., 1990). This is in contrast to what
has been observed for HCV where it was found that most noteworthy. The fact that GBV-C sometimes establishes
a chronic infection coupled with the apparent efficiencyindividuals chronically infected with HCV have antibodies
to E2 (Chien et al., 1993; Lesniewski et al., 1995) but that with which it is transmitted both parenterally (Dawson et
al., 1996; Linnen et al., 1996; Schmidt et al., 1996) andHCV does not elicit neutralizing antibodies in at least
60% of cases (Choo et al., 1994; Farci et al., 1992, 1994; vertically (Feucht et al., 1996) may explain this high preva-
lence of GBV-C exposure. Further studies will be neces-Rosa et al., 1996). It is not yet known whether there is a
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Tabrizi, A., Ching, K., Moss, B., Cummins, L. B., Houghton, M., andsary to determine whether GBV-C can also be transmitted
Muchmore, E. (1994). Vaccination of chimpanzees against infectionby insect vectors as seen for most flaviviruses.
by the hepatitis C virus. Proc. Natl. Acad. Sci. USA 91, 1294–1298.
Our results indicate that the presence of antibodies to Dawson, G. J., Schlauder, G. G., Pilot-Matias, T. J., Thiele, D., Leary,
the E2 protein appears to be a good marker of recovery T. P., Murphy, P., Rosenblatt, J. E., Simons, J. N., Martinson, F. E. A.,
from GBV-C infection. If it is ultimately determined that Gutierrez, R. A., Lentino, J. R., Pachucki, C., Muerhoff, A. S., Widell,
A., Tegtmeier, G., Desai, S., and Mushahwar, I. K. (1996). Prevalencethese antibodies are neutralizing, E2 may be a good anti-
studies of GB virus-C using reverse-transcriptase–polymerase chaingen for vaccines to protect against exposure to GBV-
reaction. J. Med. Virol. 50, 97–103.C. Moreover, the use of antisera harboring antibodies
Dille, B. J., Surowy, T. K., Gutierrez, R. A., Coleman, P. F., Knigge, M. F.,
against E2 may be an efficacious treatment for patients Carrick, R. J., Aach, R. D., Hollinger, F. B., Stevens, C. E., Barbosa,
infected with GBV-C who have not mounted an immune L. H., Nemo, G. J., Mosley, J. W., Dawson, G. J., and Mushahwar, I. K.
(1996). ELISA for the detection of antibodies to the E2 protein ofresponse sufficient to clear the virus. More immediately,
GBV-C. J. Infect. Dis., in press.serologic assays using mammalian cell-expressed GBV-
Donis, R. O., Corapi, W., and Dubovi, E. J. (1988). Neutralizing mono-C E2 protein will allow a much better assessment of
clonal antibodies to bovine diarrhoea virus bind to the 56K to 58K
the true prevalence of GBV-C in various populations and glycoprotein. J. Gen. Virol. 69, 77–86.
perhaps give a better understanding of the link between Erker, J. C., Simons, J. N., Muerhoff, A. S., Leary, T. P., Chalmers, M. L.,
Desai, S. M., and Mushahwar, I. K. (1996). Molecular cloning andGBV-C and hepatitis or other diseases. The SFV expres-
characterization of a GB virus C isolate from a patient with non-A-Esion system/GBV-C E2-336 RIPA used in this study pro-
hepatitis. J. Gen. Virol. 77, 2713–2720.vided a rapid means of identifying GBV-C E2 as a useful
Farci, P., Alter, H. J., Govindarajan, S., Wong, D. C., Engle, R., Lesniew-antigen for study of GBV-C exposure in various popula-
ski, R. R., Mushahwar, I. K., Desai, S. M., Miller, R. H., Ogata, N., and
tion groups. Since the transient expression system only Purcell, R. H. (1992). Lack of protective immunity against reinfection
takes a few days from transfection to RIPAs, it allowed with hepatitis C virus. Science 258, 135–140.
Farci, P., Alter, H. J., Wong, D. C., Miller, R. H., Govindarajan, S., Engle,a rapid assessment of correlation with RT-PCR and pro-
R., Shapiro, M., and Purcell, R. H. (1994). Prevention of hepatitis Cvided important insight into GBV-C etiology. In order to
virus infection in chimpanzees after antibody-mediated in vitro neu-better understand the clinical significance of the pres-
tralization. Proc. Natl. Acad. Sci. USA 91, 7792–7796.
ence of anti-GBV-C E2 antibodies, further studies are Feucht, H.-H., Zollner, B., Polywka, S., and Laufs, R. (1996). Vertical
being pursued with the GBV-C E2-315 ELISA, since this transmission of hepatitis G. Lancet 347, 615–616.
assay format is more amenable to larger population stud- Guirakhoo, F., Heinz, F. X., and Kunz, C. (1989). Epitope model of tick-
borne encephalitis virus envelope glycoprotein E: Analysis of struc-ies and to calculation of clinical sensitivity and specificity.
tural properties, role of carbohydrate side chains, and conformational
changes occurring at acidic pH. Virology 169, 90–99.
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